Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01043458 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic Study of ABT-126 in Stable Subjects With Schizophrenia
A Phase 1 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT01043458 is a Phase 1 study that has completed, run by Abbott. The registered enrollment target is 16 participants.
The verdict
NCT01043458, a Phase 1 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
A study to investigate the process by which ABT-126 is absorbed, distributed, metabolized and eliminated by the body of stable schizophrenic volunteers receiving treatment with an atypical antipsychotic.
Interventions
- DRUG ABT-126
- DRUG Placebo for ABT-126
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2009-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01043458
The ClinicalTrials.gov registry entry for NCT01043458 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ABT-126 is the first listed.
NCT01043458 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01043458 about?
NCT01043458 is a clinical study titled "Pharmacokinetic Study of ABT-126 in Stable Subjects With Schizophrenia". A study to investigate the process by which ABT-126 is absorbed, distributed, metabolized and eliminated by the body of stable schizophrenic volunteers receiving treatment with an atypical antipsychotic.
What is the current status of trial NCT01043458?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2009-11.
What interventions are being tested in trial NCT01043458?
The interventions under investigation include: ABT-126 (DRUG), Placebo for ABT-126 (DRUG).
Who is sponsoring clinical trial NCT01043458?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.